GSKpro for UK healthcare professionals
Ordering and delivery
Ellipta critical error studies in COPD
XEVUDY ▼ (sotrovimab)
DECTOVA▼
Report a possible side effect | GSKpro
This summer, how can GSK help you deliver the non-seasonal shingles National Immunisation Programme?
AREXVY▼
Respiratory
GSKpro Efficacy | SHINGRIX
Resources | GSKpro
OMJJARA▼
Webinars & events | GSKpro
GSKpro Implementation | SHINGRIX (Herpes Zoster vaccine recombinant, adjuvanted)
Webinars & events | GSKpro
GSK Trelegy – Homepage
Relvar Ellipta (fluticasone furoate/vilanterol)
JEMPERLI ▼
Therapy areas | GSKpro UK
Second Dose
GSKpro Patient Referrals | SHINGRIX
GSK Trelegy - Comparative Effectiveness Study
GSKpro Impact of Shingles | SHINGRIX
Vaccines
Burden of disease landing page
BLENREP▼
COPD Guidelines
Contact | GSKpro UK
Request a contact
GSKpro Home | SHINGRIX
Coming soon | GSKpro
ICS/LABA
GSKpro SHINGRIX overview | SHINGRIX
Immunocompromised | SHINGRIX
Immunocompromised Clinical Data | SHINGRIX
Discontinued products | GSK Pro
GSKpro Safety | SHINGRIX
BLENREP▼ (belantamab mafodotin) MoA | GSK UK
BLENREP ▼ (belantamab mafodotin): Multiple myeloma second-line treatment outcomes | GSK UK
DREAMM-8 BLENREP▼ (belantamab mafodotin) Trial | GSK UK
BLENREP▼ (belantamab mafodotin) : managing side effects
BLENREP▼ (belantamab mafodotin) Dosing and administration | GSK UK
Supporting patients on BLENREP▼ (belantamab mafodotin)
BLENREP ▼ (belantamab mafodotin) + Pd: Clinical trial efficacy & safety data | GSK UK
DREAMM-7 BLENREP▼ (belantamab mafodotin) Trial | GSK UK
BLENREP▼ (belantamab mafodotin) resources
BLENREP▼ (belantamab mafodotin) news and updates | GSK UK
BLENREP▼ (belantamab mafodotin) | GSK UK
Zejula (niraparib) | Get in touch
ZEJULA
Products | GSKpro
Zejula (niraparib) | Mechanism of Action in Ovarian Cancer
Zejula (niraparib) | Expert Perspectives
Zejula (niraparib) | About Zejula (niraparib)
The multiple myeloma experts | GSK UK
BLENREP▼ (belantamab mafodotin) + Vd: Clinical trial efficacy & safety data | GSK UK
Supply
IMT Guidelines
No results. Why not try:
- Checking the spelling of the search term
- Trying a different search term
- Resetting or revising the filter settings (if you used filters to do this search)
Show more
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.